Skip to main content

Participate in a Research Study

The Center for Circadian & Sleep Medicine is focused on clinical research. Learn more about our trials and participation opportunities via the search results for Northwestern Neurology on clinicaltrials.gov. Below is a selected list of our current active protocols.

Feinberg Clinical Trials

Scientists at the medical school are conducting hundreds of clinical trials daily. Learn more about all our work via the Feinberg Office of Research Clinical Trials page. Search below for trials by disease or condition.

Trials

Strengthening Circadian Signals to Enhance Cardiometabolic Functions

Purpose: The purpose of this research is to determine whether when you eat and taking melatonin (a hormone naturally produced by the body) can improve health and sleep. There is growing body of evidence that disrupted sleep and circadian rhythms have negative effects on health. The goal of this study …
Purpose: The purpose of this research is to determine whether when you eat and taking melatonin (a hormone naturally produced by the body) can improve health and sleep. There is growing body of evidence that disrupted sleep and circadian rhythms have negative effects on health. The goal of this study is to determine the impact of when you eat and melatonin on improving sleep and health in older adults who are at risk of disorders such as diabetes, heart diseases or stroke.
Eligibility Criteria:Men and women age 40-54 who have no diagnosis of diabetes or sleep disorders may be eligible for this study.
Zee, Phyllis CZee, Phyllis C
  • Map it 675 N. St. Clair St. Suite 20 100
    Chicago, IL
NCT03490864 STU00206038
More Info
Copy

A multicenter, double-blind, randomized study to evaluate the effects of tasimelteon vs. placebo in participants with Delayed Sleep-Wake Phase Disorder (DSWPD)

The purpose of this study is to evaluate the effect of aninvestigational drug called tasimelteon on the sleep-wake cycle of patientswith Delayed Sleep-Wake Phase Disorder (DSWPD) and to assess the safety oftasimelteon. Participants in this study will randomly be assigned totasimelteon or placebo, to take over a period …

The purpose of this study is to evaluate the effect of aninvestigational drug called tasimelteon on the sleep-wake cycle of patientswith Delayed Sleep-Wake Phase Disorder (DSWPD) and to assess the safety oftasimelteon. Participants in this study will randomly be assigned totasimelteon or placebo, to take over a period of 35 days. During this time,participants will be required to go to bed at certain fixed times and keep anelectronic daily sleep diary. Additionally, there will be 4 visits to yourstudy doctor's clinic, where you will be assessed for eligibility and safety.At the clinic, your study doctor will perform a physical examination, blooddraws, heart tests, questionnaires, and test your urine for drugs and alcohol.You will not be charged for any of these procedures and you may be compensatedfor your time.

If you complete the initial 35 days of the study, you willhave the option of receiving treatment with tasimelteon for up to 11 monthsafter. No matter which treatment you were randomly assigned during the first 35days, tasimelteon or placebo, you will receive tasimelteon during theadditional 11 months, if you choose to continue. During those 11 months, therewill be 4 additional visits to your study doctor's clinic (spaced 60-90 daysapart) to assess your health and safety.

  • Inclusion Criteria:

    • Ability and acceptance to provide written informed consent of the participant or legal guardian. Participants ≥ 16 and < 18 years of age will also need to provide written assent.
    • A confirmed clinical diagnosis of Delayed Sleep-Wake Phase Disorder (DSWPD).
    • Men or women between 16 - 65 years, inclusive.
    • Body Mass Index (BMI) of ≥ 18 and ≤ 30 kg/m^2.

  • Exclusion Criteria:
    • History of psychiatric disorders within 12 months.
    • Major surgery, trauma, illness, general anesthesia, or immobility for 3 or more days within the last 30 days.
    • Pregnancy, recent pregnancy (within 6 weeks), or women who are breastfeeding.
    • A positive test for substances of abuse
Zee, Phyllis CZee, Phyllis C
  • Map it 676 N. Saint Clair St. Seventh Floor, Suite 701
    Chicago, IL
  • Map it 259 E. Erie St. Lavin Pavillion, Suite 19 100
    Chicago, IL
NCT04652882 STU00213922
More Info
Copy